Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Melanoma: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Melanoma. According to GlobalData, Phase...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer. According...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Solid Tumor: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData,...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Renal Cell Carcinoma: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Renal Cell Carcinoma. According to...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData,...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Hepatocellular Carcinoma: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Breast Cancer: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Breast Cancer. According to GlobalData,...
ZX-4081 by Hangzhou Zenshine Pharmaceuticals for Ovarian Cancer: Likelihood of Approval
ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData,...